JP2003516325A5 - - Google Patents

Download PDF

Info

Publication number
JP2003516325A5
JP2003516325A5 JP2001541001A JP2001541001A JP2003516325A5 JP 2003516325 A5 JP2003516325 A5 JP 2003516325A5 JP 2001541001 A JP2001541001 A JP 2001541001A JP 2001541001 A JP2001541001 A JP 2001541001A JP 2003516325 A5 JP2003516325 A5 JP 2003516325A5
Authority
JP
Japan
Prior art keywords
epilepsy
stroke
group
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001541001A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003516325A (ja
JP4021195B2 (ja
Filing date
Publication date
Priority claimed from US09/454,136 external-priority patent/US6605597B1/en
Application filed filed Critical
Publication of JP2003516325A publication Critical patent/JP2003516325A/ja
Publication of JP2003516325A5 publication Critical patent/JP2003516325A5/ja
Application granted granted Critical
Publication of JP4021195B2 publication Critical patent/JP4021195B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2001541001A 1999-12-03 2000-12-01 部分もしくは完全a1アゴニスト:n6複素環式5′−チオ置換アデノシン誘導体 Expired - Fee Related JP4021195B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/454,136 1999-12-03
US09/454,136 US6605597B1 (en) 1999-12-03 1999-12-03 Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
PCT/US2000/032721 WO2001040246A1 (en) 1999-12-03 2000-12-01 Partial or full a1 agonists - n6 heterocyclic 5'-thio substituted adenosine derivatives

Publications (3)

Publication Number Publication Date
JP2003516325A JP2003516325A (ja) 2003-05-13
JP2003516325A5 true JP2003516325A5 (cg-RX-API-DMAC7.html) 2007-10-11
JP4021195B2 JP4021195B2 (ja) 2007-12-12

Family

ID=23803455

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001541001A Expired - Fee Related JP4021195B2 (ja) 1999-12-03 2000-12-01 部分もしくは完全a1アゴニスト:n6複素環式5′−チオ置換アデノシン誘導体

Country Status (25)

Country Link
US (2) US6605597B1 (cg-RX-API-DMAC7.html)
EP (1) EP1233973B1 (cg-RX-API-DMAC7.html)
JP (1) JP4021195B2 (cg-RX-API-DMAC7.html)
KR (1) KR100484988B1 (cg-RX-API-DMAC7.html)
CN (1) CN1152042C (cg-RX-API-DMAC7.html)
AR (1) AR029199A1 (cg-RX-API-DMAC7.html)
AT (1) ATE254133T1 (cg-RX-API-DMAC7.html)
AU (3) AU4138701A (cg-RX-API-DMAC7.html)
BR (1) BR0016126A (cg-RX-API-DMAC7.html)
CA (1) CA2389264C (cg-RX-API-DMAC7.html)
CZ (1) CZ20013705A3 (cg-RX-API-DMAC7.html)
DE (1) DE60006576T2 (cg-RX-API-DMAC7.html)
DK (1) DK1233973T3 (cg-RX-API-DMAC7.html)
ES (1) ES2208437T3 (cg-RX-API-DMAC7.html)
HK (1) HK1047941A1 (cg-RX-API-DMAC7.html)
HU (1) HUP0500455A2 (cg-RX-API-DMAC7.html)
IL (1) IL145903A (cg-RX-API-DMAC7.html)
MX (1) MXPA01011113A (cg-RX-API-DMAC7.html)
NO (1) NO20015373L (cg-RX-API-DMAC7.html)
NZ (1) NZ514777A (cg-RX-API-DMAC7.html)
PT (1) PT1233973E (cg-RX-API-DMAC7.html)
TR (2) TR200103129T2 (cg-RX-API-DMAC7.html)
TW (1) TWI249536B (cg-RX-API-DMAC7.html)
WO (2) WO2001040243A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200204380B (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47351E1 (en) 1999-06-22 2019-04-16 Gilead Sciences, Inc. 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists
US6214807B1 (en) * 1999-06-22 2001-04-10 Cv Therapeutics, Inc. C-pyrazole 2A A receptor agonists
US6403567B1 (en) * 1999-06-22 2002-06-11 Cv Therapeutics, Inc. N-pyrazole A2A adenosine receptor agonists
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
CA2671940A1 (en) 2000-02-23 2001-08-30 Cv Therapeutics, Inc. Identification of partial agonists of the a2a adenosine receptor
GB2372741A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,8-Disubstituted adenosine derivatives and their different uses
GB2372742A (en) * 2001-03-03 2002-09-04 Univ Leiden C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) * 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
WO2003070739A1 (en) * 2002-02-19 2003-08-28 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
ATE418991T1 (de) * 2002-04-18 2009-01-15 Cv Therapeutics Inc Methode zur behandlung von herzrhythmusstörungen mit einem a1 adenosin agonist zusammen mit einem beta blocker
WO2004011010A1 (en) * 2002-07-29 2004-02-05 Cv Therapeutics, Inc. Myocardial perfusion imaging using a2a receptor agonists
US20050020915A1 (en) * 2002-07-29 2005-01-27 Cv Therapeutics, Inc. Myocardial perfusion imaging methods and compositions
US8470801B2 (en) 2002-07-29 2013-06-25 Gilead Sciences, Inc. Myocardial perfusion imaging methods and compositions
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
JP2007509180A (ja) 2003-10-21 2007-04-12 インスパイアー ファーマシューティカルズ,インコーポレイティド 疼痛を治療するための、非ヌクレオチド組成物および方法
DE602004027409D1 (de) 2003-10-21 2010-07-08 Inspire Pharmaceuticals Inc Tetrahydrofuroä3,4-düdioxolverbindungen und zusammensetzungen und verfahren zur inhibierung der trombozytenaggregation
US7749981B2 (en) 2003-10-21 2010-07-06 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with non-nucleotide P2Y12 receptor antagonist compound
US7335648B2 (en) 2003-10-21 2008-02-26 Inspire Pharmaceuticals, Inc. Non-nucleotide composition and method for inhibiting platelet aggregation
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
EP1802317A2 (en) * 2004-10-20 2007-07-04 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists
US7932376B2 (en) 2005-05-05 2011-04-26 Inspire Pharmaceuticals, Inc. Pyrimidine-based non-nucleotide composition and method for inhibiting platelet aggregation
SI1881823T1 (sl) * 2005-05-17 2015-04-30 Sarcode Bioscience Inc. Sestavki in postopki za zdravljenje bolezni oäśesa
BRPI0619261A2 (pt) * 2005-11-30 2011-09-27 Inotek Pharmaceuticals Corp derivados de purina e métodos de uso desses
CA2640089C (en) 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Process for preparing an a2a-adenosine receptor agonist and its polymorphs
WO2007107598A1 (en) 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Phosphorylated a2a receptor agonists
CA2655310A1 (en) * 2006-06-22 2008-05-29 Cv Therapeutics, Inc. Use of a2a adenosine receptor agonists in the treatment of ischemia
MX2009002299A (es) * 2006-09-01 2009-03-20 Cv Therapeutics Inc Metodos y composiciones para incrementar la tolerancia del paciente durante metodos de formacion de imagenes del miocardio.
US20090081120A1 (en) * 2006-09-01 2009-03-26 Cv Therapeutics, Inc. Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods
WO2008042796A2 (en) * 2006-09-29 2008-04-10 Cv Therapeutics, Inc. Methods for myocardial imaging in patients having a history of pulmonary disease
EP2099360A2 (en) * 2007-01-03 2009-09-16 CV Therapeutics Inc. Myocardial perfusion imaging
CA2702984C (en) 2007-10-19 2017-04-11 Sarcode Corporation Compositions and methods for treatment of diabetic retinopathy
US20110064671A1 (en) 2008-03-10 2011-03-17 Cornell University Modulation of blood brain barrier permeability
EP2276508A4 (en) * 2008-04-15 2011-12-28 Sarcode Bioscience Inc ADMINISTRATION OF LFA-1 ANTAGONISTS TO THE GASTROINTESTINAL SYSTEM
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
CN102065694A (zh) * 2008-04-15 2011-05-18 萨可德公司 用于局部治疗免疫相关疾病的雾化的lfa-1拮抗剂
EP3632444A3 (en) * 2008-04-15 2020-08-26 SARcode Bioscience Inc. Topical lfa-1 antagonists for use in localized treatment of immune related disorders
KR20110063556A (ko) * 2008-09-29 2011-06-10 길리애드 사이언시즈, 인코포레이티드 다검출 전산화 단층 촬영법에 사용하기 위한 a-2-알파 수용체 길항제와 속도 조절제의 조합물
US8378105B2 (en) * 2009-10-21 2013-02-19 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
CN101934559B (zh) * 2010-08-12 2013-04-17 中国电子科技集团公司第四十五研究所 具有压力调节机构的砂浆供给装置
EP2877465A4 (en) 2012-07-25 2016-05-11 Sarcode Bioscience Inc LFA-1 HEMMER AND POLYMORPH THEREOF

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4373097A (en) 1981-04-27 1983-02-08 Bioresearch S.R.L. Process for preparing adenosine derivatives of anti-inflammatory and analgesic activity
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
CN1065529C (zh) * 1994-06-09 2001-05-09 爱斯制药株式会社 4-喹啉酮衍生物及其盐
US5789416B1 (en) * 1996-08-27 1999-10-05 Cv Therapeutics Inc N6 mono heterocyclic substituted adenosine derivatives
GB9723566D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
GB9723590D0 (en) * 1997-11-08 1998-01-07 Glaxo Group Ltd Chemical compounds
US6258793B1 (en) * 1999-12-03 2001-07-10 Cv Therapeutics, Inc. N6 heterocyclic 5′ modified adenosine derivatives
US6605597B1 (en) * 1999-12-03 2003-08-12 Cv Therapeutics, Inc. Partial or full A1agonists-N-6 heterocyclic 5′-thio substituted adenosine derivatives
US6294522B1 (en) * 1999-12-03 2001-09-25 Cv Therapeutics, Inc. N6 heterocyclic 8-modified adenosine derivatives

Similar Documents

Publication Publication Date Title
JP2003503454A5 (cg-RX-API-DMAC7.html)
CA2366268A1 (en) Pharmaceutical compositions for cns and other disorders
JP2002502871A5 (cg-RX-API-DMAC7.html)
AU2002225772A1 (en) Therapeutic agents and methods of use thereof for treating an amyloidogenic disease
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
HRP20220902T3 (hr) Pripravci i njihova upotreba u liječenju multiple skleroze
JP2022153638A5 (cg-RX-API-DMAC7.html)
JP2002511411A5 (cg-RX-API-DMAC7.html)
JP2002532392A5 (cg-RX-API-DMAC7.html)
HUP0201623A3 (en) Use of (s,s)reboxetine a selective norepinephrine reuptake inhibitor for the preparation of pharmaceutical compositions treating disorders of the nervous system
CA2307018A1 (en) Osmotic medicament releasing system
WO2002058620A3 (es) Composiciones farmaceuticas que contienen un inhibidor de cox-ii y un relajante muscular
CA2364718A1 (en) Monoamine reuptake inhibitors for treatment of cns disorders
BG108131A (en) Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
HRP20110497T4 (hr) Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem
AU2001266152A1 (en) Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
Bacsik et al. Toxic systemic reactions of bupivacaine and etidocaine
AR040248A1 (es) Farmaco para el tratamiento de la vejiga hiperactiva
TW197423B (cg-RX-API-DMAC7.html)
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
AR001765A1 (es) Una formulación de liberación prolongada un procedimiento para su preparación una forma cristalina de cisaprida-(l)-tartrato y un medicamento util para el tratamiento de trastornos gastrointestinales
HUP0301578A3 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders and pharmaceutical compositions containing them
EE05174B1 (et) Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette n„htud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks
JP2005527477A5 (cg-RX-API-DMAC7.html)